AstraZeneca entered into a two-year collaboration with Singapore’s top notch research and clinical groups including the Agency for Science, Technology and Research (A*STAR), National University Heart Centre, Singapore (NUHCS) and National University of Singapore.
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.
AstraZeneca and the Singapore teams has recognized the importance of the less studied variation of heart failure with preserved ejection fraction (HFpEF). According to the Singapore Heart Foundation, 1 out of 3 deaths in Singapore is due to heart diseases or stroke. This complex syndrome HFpEF, although equally common as heart failure, causes the heart to stiffen and shrink in contrast to the conventional enlarged heart during heart failure.
HFpEF patients are more often older women with frequent hypertension, low incidence of coronary artery disease, and breathlessness. This collaboration aims to utilize high quality clinical data obtained from the Singapore Heart Failure Outcomes & Phenotypes (SHOP) study with patients of Asian ethnicity to investigate the molecular mechanisms driving HFpEF and further to identify novel biomarkers for diagnostic and therapeutic purposes. The outcomes of these studies will help further AstraZeneca’s population-driven cardiovascular therapeutic initiatives.
You can read the official press release from AstraZeneca here.